Platform Application Development
Oncology (Neoantigen Detection)
Key Facts
About Erisyon
Erisyon is a private, pre-revenue biotech company commercializing a transformative single-molecule protein sequencing technology called Fluorosequencing. The platform, invented at the University of Texas at Austin, offers ultimate sensitivity, massively parallel throughput, and absolute quantification, positioning it to address critical gaps in proteomics left by mass spectrometry and RNA sequencing. Erisyon is initially targeting applications in oncology, neurology, and infectious disease, with the goal of fundamentally changing how diseases are detected, treated, and monitored.
View full company profileAbout Erisyon
Erisyon is a private, pre-revenue biotech company commercializing a transformative single-molecule protein sequencing technology called Fluorosequencing. The platform, invented at the University of Texas at Austin, offers ultimate sensitivity, massively parallel throughput, and absolute quantification, positioning it to address critical gaps in proteomics left by mass spectrometry and RNA sequencing. Erisyon is initially targeting applications in oncology, neurology, and infectious disease, with the goal of fundamentally changing how diseases are detected, treated, and monitored.
View full company profileAbout Erisyon
Erisyon is a private, pre-revenue biotech company commercializing a transformative single-molecule protein sequencing technology called Fluorosequencing. The platform, invented at the University of Texas at Austin, offers ultimate sensitivity, massively parallel throughput, and absolute quantification, positioning it to address critical gaps in proteomics left by mass spectrometry and RNA sequencing. Erisyon is initially targeting applications in oncology, neurology, and infectious disease, with the goal of fundamentally changing how diseases are detected, treated, and monitored.
View full company profile